Multi-center Clinical Study on Neonatal Hyperbilirubinemia
Multi-center Clinical Study on Early Screening and Treatment of Hyperbilirubinemia of Term and Late-preterm Neonates
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210000
- Nanjing Maternity and Child Health Care Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
term or near-term neonates with gestational age ≥35w and birth weight ≥2000g.
Exclusion Criteria:
Infants admitted to a higher level of intervention before discharge.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
NO_INTERVENTION: Before-intervention phase
All the healthy infants who were admitted from March 2018 to August 2018 to the Well Baby nurse of different hospitals.
|
|
|
EXPERIMENTAL: Intervention phase
All the healthy infants who were admitted from September 2018 to February 2019 to the Well Baby nurse of different hospitals.During this phase,multiple intervention bundles of quality improvement will be implemented.
|
During the Intervention phase and Sustainability phase ,The hospitals will receive training of multiple evidence based quality improvement methods.
|
|
EXPERIMENTAL: Sustainability intervention phase
All the healthy infants who were admitted from March 2019 to August 2019 to the Well Baby nurse of different hospitals.In the Sustainability intervention phase,multiple intervention bundles of quality improvement will be continuous implemented.
|
During the Intervention phase and Sustainability phase ,The hospitals will receive training of multiple evidence based quality improvement methods.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The incidence of bilirubin encephalopathy
Time Frame: 18 months
|
18 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The incidence of severe hyperbilirubinemia
Time Frame: 18 months
|
Severe hyperbilirubinemia:total serum bilirubin more than 20mg/dL
|
18 months
|
|
The rate of lost to follow-up
Time Frame: 18 months
|
The rate of lost to follow-up for jaundice after discharge from well-baby nursery
|
18 months
|
|
The incidence of adverse neurological outcomes in patients with severe hyperbilirubinemia
Time Frame: 42 months
|
Patients with severe hyperbilirubinemia from 11 hospitals will be followed to investigate their neurological outcomes until 24 months after birth
|
42 months
|
|
Medical costs in patients with severe hyperbilirubinemia
Time Frame: 18 months
|
To compare the medical costs in patients with severe hyperbilirubinemia from 3 phases of quality improvement.
|
18 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Zhiyong Sun, PHD, JiLin Women and Children Health Hospital
- Principal Investigator: Haiyan Cai, PHD, Qinhuangdao Maternal and Child Health Care Hospital
- Principal Investigator: Yonghui Yu, MD, Shandong Provincial Hospital
- Principal Investigator: Xin Yuan, MD, Shan Dong Qian Fo Shan Hospital
- Principal Investigator: Jin Qian, MD, Shan Dong Liao Cheng Hospital
- Principal Investigator: Wenyan Tang, PHD, Jiangxi Maternal and Child Health Hospital
- Principal Investigator: Zhankui Li, PHD, Northwest Women's and Children's Hospital, Xi'an, Shaanxi
- Principal Investigator: Jie Gu, PHD, Yin Chuan Maternity and Child Health Hospital
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NMU-FY2018-72
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.